Literature DB >> 20107901

Genotype-phenotype correlations: sudden death in an infant with very-long-chain acyl-CoA dehydrogenase deficiency.

Curtis R Coughlin1, Can Ficicioglu.   

Abstract

Very-long-chain acyl-coenzyme A (CoA) dehydrogenase deficiency (VLCADD) is an autosomal recessive disorder of fatty acid oxidation. The phenotype of VLCADD is heterogeneous, and patients are typically classified into three categories based upon onset of symptoms and clinical findings. As a result of early diagnosis and treatment, many patients with VLCADD have remained asymptomatic. A general genotype-phenotype correlation has been elicited. A genotype that is associated with residual enzyme activity is more likely to present with an attenuated phenotype. One prevailing mutation, the c.848T>C (p.V283A), has been associated with residual enzyme activity and has been identified in many asymptomatic individuals diagnosed through either newborn or family screening. We present a patient who died as a result of fatal hypoglycemia at 38 h of life before diagnosis of VLCADD could be established by newborn screening. Despite the early onset of the disease, the patient was found to have a missense mutation within the ACADVL gene with a c.848T>C, c.342+1G>C genotype. Genotype alone remains limited in its predictive ability to determine which affected individuals are at risk for fatal complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107901     DOI: 10.1007/s10545-009-9041-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  6 in total

Review 1.  Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2012-06       Impact factor: 5.695

2.  Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States.

Authors:  Marcus J Miller; Lindsay C Burrage; James B Gibson; Meghan E Strenk; Edward J Lose; David P Bick; Sarah H Elsea; V Reid Sutton; Qin Sun; Brett H Graham; William J Craigen; Victor Wei Zhang; Lee-Jun C Wong
Journal:  Mol Genet Metab       Date:  2015-09-02       Impact factor: 4.797

Review 3.  Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.

Authors:  Kenji Yamada; Takeshi Taketani
Journal:  J Hum Genet       Date:  2018-11-06       Impact factor: 3.172

4.  Four Years' Experience in the Diagnosis of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency in Infants Detected in Three Spanish Newborn Screening Centers.

Authors:  B Merinero; P Alcaide; E Martín-Hernández; A Morais; M T García-Silva; P Quijada-Fraile; C Pedrón-Giner; E Dulin; R Yahyaoui; J M Egea; A Belanger-Quintana; J Blasco-Alonso; M L Fernandez Ruano; B Besga; I Ferrer-López; F Leal; M Ugarte; P Ruiz-Sala; B Pérez; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2017-07-29

5.  Misclassification of VLCAD carriers due to variable confirmatory testing after a positive NBS result.

Authors:  Anne E Atkins; Beth A Tarini; Emily K Phillips; Amy R U L Calhoun
Journal:  J Community Genet       Date:  2019-02-05

6.  Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database.

Authors:  Loren D M Pena; Sandra C van Calcar; Joyanna Hansen; Mathew J Edick; Cate Walsh Vockley; Nancy Leslie; Cynthia Cameron; Al-Walid Mohsen; Susan A Berry; Georgianne L Arnold; Jerry Vockley
Journal:  Mol Genet Metab       Date:  2016-05-13       Impact factor: 4.797

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.